Granules India board clears proposal to set up subsidiary in Hyderabad

Published On 2020-11-10 06:09 GMT   |   Update On 2020-11-10 06:26 GMT

New Delhi: Drug firm Granules India on Monday said its board has approved a proposal to set up a subsidiary in Hyderabad to build a greenfield facility for formulations business."The Board of Directors at their meeting has approved to incorporate a wholly-owned subsidiary of the company in Hyderabad, India to build a greenfield facility for formulations business," Granules said in a...

Login or Register to read the full article

New Delhi: Drug firm Granules India on Monday said its board has approved a proposal to set up a subsidiary in Hyderabad to build a greenfield facility for formulations business.

"The Board of Directors at their meeting has approved to incorporate a wholly-owned subsidiary of the company in Hyderabad, India to build a greenfield facility for formulations business," Granules said in a regulatory filing.

The company, however, did not share more details, reports PTI.

Read also: Granules, Laurus Labs to invest Rs 700 crores for setting up Greenfield facilities

Granules India is an Indian pharmaceutical manufacturing company that was founded in 1984 named as Triton Laboratories located in Hyderabad, India.

Granules manufactures varieties of drugs including Paracetamol, Ibuprofen, Metformin, and Guaifenesin, on a large scale for customers in the domestic as well as international markets.



Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News